Neuroprotective methods and reagents
AssigneeCuris, Inc.
InventorNagesh K. Mahanthappa
Life of this patent
Estimating the term…
Abstract
One aspect of the present application relates to a method for limiting damage to neuronal cells by ischemic or epoxic conditions, e.g., such as may be manifest by a reduction in brain infarct volume, by administering to an individual a hedgehog therapeutic or ptc therapeutic in an amount effective for reducing cerebral infarct volume.
Claims28
A method for prophylactically limiting damage to neuronal cells by ischemic or hypoxic conditions, comprising systemically administering to an individual in need thereof an effective amount of an agent for promoting hedgehog signaling to prophylactically protect cells and limit damage to neuronal cells by ischemic or hypoxic conditions, wherein the agent for promoting hedgehog signaling is selected from a mammalian Sonic hedgehog polypeptide or a protein kinase A (PKA) inhibitor that selectively inhibits PKA activity over protein kinase C (PKC) activity.
A method for prophylactically protecting cerebral tissue of a mammal against the repercussions of ischemia which comprises systemically administering to a mammal in need thereof a therapeutically effective amount of an agent for promoting hedgehog signaling to prophylactically protect cerebral tissue in said mammal, wherein the agent for promoting hedgehog signaling is selected from a mammalian Sonic hedgehog polypeptide or a protein kinase A (PKA) inhibitor that selectively inhibits PKA activity over protein kinase C (PKC) activity.
A method for treating cerebral infarction, comprising systemically administering to a patient in need thereof a therapeutically effective amount of an agent for promoting hedgehog signaling for reducing cerebral infarct volume, wherein the agent for promoting hedgehog signaling is selected from a mammalian Sonic hedgehog polypeptide or a protein kinase A (PKA) inhibitor that selectively inhibits PKA activity over protein kinase C (PKC) activity.
A method for treating cerebral ischemia which comprises systemically administering to a patient in need thereof a therapeutically effective amount of an agent for promoting hedgehog signaling, wherein the agent for promoting hedgehog signaling is selected from a mammalian Sonic hedgehog polypeptide or a protein kinase A (PKA) inhibitor that selectively inhibits PKA activity over protein kinase C (PKC) activity.
A method for the treatment of stroke which comprises systemically administering to a patient in need thereof a therapeutically effective amount of an agent for promoting hedgehog signaling, wherein the agent for promoting hedgehog signaling is selected from a mammalian Sonic hedgehog polypeptide or a protein kinase A (PKA) inhibitor that selectively inhibits PKA activity over protein kinase C (PKC) activity.
A method for the treatment of transient ischemic attack which comprises systemically administering to a patient in need thereof a therapeutically effective amount of an agent for promoting hedgehog signaling, wherein the agent for promoting hedgehog signaling is selected from a mammalian Sonic hedgehog polypeptide or a protein kinase A (PKA) inhibitor that selectively inhibits PKA activity over protein kinase C (PKC) activity.
Dependencies are inferred from the claim text.